A clear look at the 340B program: how hospitals generate revenue from drug discounts, why it has expanded, and the growing ...

B 2026 tracking litigation highlights drugmaker mandates and legal challenges reshaping hospital drug pricing and compliance risks.

A recent congressional hearing on 340B is the latest iteration of a standoff between two pillars of the healthcare industry—hospitals and pharmaceutical manufacturers—both of which have powerful ...

Drug companies are more likely than hospitals to violate 340B regulations, according to a recent American Hospital Association report. The 340B Drug Pricing Program has been under constant attack on ...

On July 31, 2025, the Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA) issued a 340B Drug Pricing Program notice (the “Notice”) announcing the launch of a ...

The 340B Drug Pricing Program was created in 1992 to increase access to hospital outpatient medications for low‐income and uninsured patients by allowing covered entities that serve these patients to ...

On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical ...

"As the 340B program grows across sectors, the administrative complexity of the program has also expanded in ways that elected officials, regulators and others involved in the program may not be fully ...

Most government support programs provide benefits directly to people, whether it is SNAP (Supplemental Nutritional Assistance Program), TANF (Temporary Assistance for Needy Families), or housing ...

It’s no surprise that chronic illness and affordability challenges can cause job loss, slow up wage gain and prevent work entirely. All Americans don’t share this burden equally, though. Minorities — ...